HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis

Journal of Clinical Oncology

Volumn 22, Issue 5, 2004, Pages 854-863

  Elkin, Elena B ^a   Weinstein, Milton C ^a   Winer, Eric P ^a   Kuntz, Karen M ^a   Schnitt, Stuart J ^a   Weeks, Jane C ^a  

^a HARVARD CENTER FOR RISK ANALYSIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; MONOCLONAL ANTIBODY;

AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION; BREAST TUMOR; CANCER INVASION; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DECISION SUPPORT SYSTEM; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COST; ECONOMICS; FEMALE; GENETIC SCREENING; GENETICS; HEALTH CARE COST; MORTALITY; PATHOLOGY; PROBABILITY; PROTO ONCOGENE; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; COHORT STUDIES; COST SAVINGS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; GENES, ERBB-2; GENETIC SCREENING; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 1542503725     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.04.158     Document Type: Article

References (91)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
3. Slamon D, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
4. Kay EW, Walsh CJ, Cassidy M. et al: C-erbB-2 immunostaining: Problems with interpretation. J Clin Pathol 47:816-822, 1994
5. Hoang MP, Sahin A, Ordonez NG, et al: HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 113:852-859, 2000
6. Thomson TA, Hayes MM, Spinelli JJ, et al: HER-2/neu in breast cancer: Interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 14:1079-1086, 2001
7. Tsuda H, Akiyama F, Terasaki H, et al: Detection of HER-2/neu (c-erb-B-2) DNA amplification in primary breast carcinoma: Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 92:2965-2974, 2001
8. Hsu C, Ho DM, Yang C, et al: Interobserver reproducibility of HER-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. Am J Clin Pathol 118:693-698, 2002
9. Jacobs TW, Gown AM, Yaziji H, et al: HER-2/neu protein overexpression in breast cancer evaluated by immunohistochemistry: A study of interlaboratory agreement. Am J Clin Pathol 113:251-258, 2000
10. Gancberg D, Jarvinen T, di Leo A, et al: Evaluation of HER-2/NEU protein overexpression in breast cancer by immunohistochemistry: An interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat 74:113-120, 2002
11. Paik S, Bryant J, Tan-Chiu E, et al: Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel project experience. J Natl Cancer Inst 94:852-854, 2002
12. Rhodes A, Jasani B, Anderson E, et al: Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: A comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 118:408-417, 2002
13. Roche PC, Suman VJ, Jenkins RB, et al: Concordance between local and central laboratory HER2 testing in the Breast Intergroup trial N9831. J Natl Cancer Inst 94:855-857, 2002
14. Dowsett M, Bartlett J, Ellis IO, et al: Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 199:418-423, 2003
15. Mass R, Sanders C, Kasian C, et al: The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc Am Soc Clin Oncol 19:75a, 2000 (abstr 291)
16. Mass RD, Press M, Anderson S, et al: Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization. Proc Am Soc Clin Oncol 20:22a, 2001 (abstr 85)
17. Press MF, Slamon D, Cobleigh M, et al: Improved clinical outcomes for Herceptin-treated patients selected by fluorescence in situ hybridization (FISH). Lab Invest 82:47A, 2002 (abstr 185)
18. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
19. Lebeau A, Deimling D, Kaltz C, et al: HER-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19:354-363, 2001
20. Wang S, Saboorian MH, Frenkel E, et al: Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridization. J Clin Pathol 53:374-381, 2000
21. Perez EA, Roche PC, Jenkins RB, et al: HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 77:148-154, 2002
22. Hunink M, Glasziou P, Siegel J, et al: Decision-Making in Health and Medicine: Integrating Evidence and Values. New York, NY, Cambridge University Press, 2001
23. HercepTest [package insert]. Carpinteria, CA, DAKO Corp, 2001
24. Kallioniemi O, Kallioniemi A, Kurisu W, et al: ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A 89:5321-5325, 1992
25. Press MF, Hung G, Godolphin W, et al: Sensitivity of Her-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54:2771-2777, 1994
26. Espinoza F, Anguiano A: The HercepTest assay: Another perspective. J Clin Oncol 17:2293-2294, 1999 [letter]
27. Farabegoli F, Ceccarelli C, Santini D, et al: C-erbB-2 overexpression in amplified and non-amplified breast carcinoma samples. Int J Cancer 84:273-277, 1999
28. Harbeck N, Ross JS, Yurdseven S, et al: HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. Int J Oncol 14:663-671, 1999
29. Jacobs TW, Gown AM, Yaziji H, et al: Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 17:1974-1982, 1999
30. Jacobs TW, Gown AM, Yaziji H, et al: Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17:1983-1987, 1999
31. Couturier J, Vincent-Salomon A, Nicolas A, et al: Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 13:1238-1243, 2000
32. Pauletti G, Dandekar S, Rong H, et al: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651-3664, 2000
33. Jiminez RE, Wallis T, Tabasczka P, et al: Determination of Her-2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 13:37-45, 2000
34. Hanna WM, Kahn HJ, Pienkowska M, et al: Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. Mod Pathol 14:677-685, 2001
35. Harris LN, Liotcheva V, Broadwater G, et al: Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 19:1698-1706, 2001
36. Onody P, Bertrand F, Muzeau F, et al: Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination: Application to node-negative breast cancer. Arch Path Lab Med 125:746-750, 2001
37. Simon R, Nocito A, Hubscher T, et al: Patterns of HER-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 93:1141-1146, 2001
38. Tubbs RR, Pettay JD. Roche PC, et al: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19:2714-2721, 2001
39. Bozzetti C, Nizzoli GA, Flora M, et al: HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Ann Oncol 13:1398-1403, 2002
40. Kobayashi M, Ooi A, Oda Y, et al: Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: A comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues. Hum Pathol 33:21-28, 2002
41. Larsimont D, Di Leo A, Rouas G, et al: HER-2/Neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: Implications for daily laboratory practice. Anticancer Res 22:2485-2490, 2002
42. Press MF, Slamon DJ, Flom KJ, et al: Evaluation of HER-2/neu gene amplification and protein overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20:3095-3105, 2002
43. Rhodes A, Jasani B, Couturier J, et al: A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol 117:81-89, 2002
44. Wang s, Saboorian MH, Frenkel EP, et al: Aneusomy 17 in breast cancer: Its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol 15:137-145, 2002
45. Xu R, Perle MA, Inghirami G, et al: Amplification of the Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 15:116-124, 2002
46. Bartlett JMS, Going JJ, Mallon EA, et al: Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 195:422-428, 2001
47. Birner P, Oberhuber G, Stani J, et al: Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7:1669-1675, 2001
48. McCormick SR, Lillemoe TJ, Beneke J, et al: HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: Comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol 117:935-943, 2002
49. Ridolfi RL, Jamehdor MR, Arber JM: HER-2/neu testing in breast carcinoma: A combined immunohitochemical and fluorescence in situ hybridization approach. Mod Pathol 13:866-873, 2000
50. Seidman AD, Fornier M, Esteva F, et al: Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19:2587-2595, 2001
51. Cianciulli AM, Botti C, Coletta AM, et al: Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer. Cancer Genet Cytogenet 133:66-71, 2002
52. Bhargava R, Naeem R, Marconi S, et al: Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression. Hum Pathol 32:1344-1350, 2001
53. Ross JS, Fletcher JA: The HER-2/neu oncogene: Prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 9:125-138, 1999
54. Ewer MS, Gibbs HR, Swafford J, et al: Cardiotoxicity in patients receiving trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin Oncol 26:96-101, 1999
55. Press MF, Bernstein L, Thomas PA, et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894-2904, 1997
56. Press MF, Pike MC, Chazin VR, et al: Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960-4970, 1993
57. Gold MR, Siegel JE, Russell LB, et al: Cost-Effectiveness in Health and Medicine. New York, NY, Oxford University Press, 1996
58. Brown RE, Hutton J: Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. AntiCancer Drugs 9:899-907, 1998
59. Earle CC, Chapman RH, Baker CS, et al: Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18:3302-3317, 2000
60. Centers for Medicare and Medicaid Services: Medicare program; Revisions to payment policies and five-year review of and adjustments to the relative value units under the physician fee schedule for calendar year 2002; Final rule. Federal Register 66:55246-55503, 2001
61. Centers for Medicare and Medicaid Services: 2002 Clinical Laboratory Fee Schedule (revised December 5, 2001), US Department of Health and Human Services, 2001
62. Drug Topics Red Book. Montvale, NJ, Medical Economics, 2002
63. Bristol-Myers Squibb: Prescribing information for Taxol (paclitaxel) injection. Princeton, NJ, Bristol-Myers Squibb, 1998
64. US Department of the Treasury: Travel, entertainment, gift, and car expenses (IRS Publication 463). Washington, DC, Internal Revenue Service Technical Publications Branch, 2001
65. Bureau of Labor Statistics: Current Population Survey, March Supplement. US Department of Labor, 2002
66. Fireman BH, Quesenberry CP, Somkin CP, et al: Cost of care for cancer in a health maintenance organization. Health Care Financ Rev 18:51-75, 1997
67. Khoury MJ, Morris J: Pharmacogenomics and public health: The promise of targeted disease prevention, 12/02 update. http://www.cdc.gov/genomics/info/ factshts/pharmacofs.htm
68. Osoba D, Burchmore M: Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin). Semin Oncol 26:84-88, 1999
69. Osoba D, Slamon DJ, Burchmore M, et al: Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 20:3106-3113, 2002
70. Cook-Bruns N: Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 61(suppl 2):58-66, 2001
71. American Society of Clinical Oncology: Reform of the Medicare payment methods for cancer chemotherapy. Alexandria, VA, American Society of Clinical Oncology, 2001
72. U. S. General Accounting Office: Payments for outpatient drugs exceed providers' cost. Washington, DC, U. S. General Accounting Office, 2001
73. Hayman JA, Hillner BE, Harris JR, et al: Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. J Clin Oncol 16:1022-1029, 1998
74. Hillner BE, Smith TJ: Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer: A decision analysis model. N Engl J Med 324:160-168, 1991
75. Lee JH, Glick HA, Hayman JA, et al: Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients. J Clin Oncol 20:2713-2725, 2002
76. Smith TJ, Hillner BE: The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 11:771-776, 1993
77. Hillner BE, Weeks JC, Smith TJ, et al: Pamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 18:72-79, 2000
78. Orr RK, Col NF, Kuntz KM: A cost-effectiveness analysis of axillary node dissection in post-menopausal women with estrogen receptor positive breast cancer and clinically negative axillary nodes. Surgery 126:568-576, 1999
79. Cremieux PY, Finkelstein SN, Berndt ER, et al: Cost effectiveness, quality-adjusted life-years and supportive care: Recombinant human erythropoietin as a treatment of cancer-associated anaemia. Pharmacoecon 16:459-472, 1999
80. Zbrozek AS, Cantor SB, Cardenas MP, et al: Pharmacoeconomic analysis of ondansetron versus metaclopramide for cisplatin-induced nausea and vomiting. Am J Hosp Pharm 51:1555-1563, 1994
81. Ubel PA, Hirth RA, Chernew ME, et al: What is the price of life and why doesn't it increase at the rate of inflation? Arch Internal Med 163:1637-1641, 2003
82. Pauletti G, Godolphin W, Press MF, et al: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72, 1996
83. Persons DL, Borelli KA, Hsu PH: Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 10:720-727, 1997
84. Robertson KW, Reeves JR, Smith G, et al: Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res 56:3823-3830, 1996
85. Lehr H, Jacobs TW, Yaziji H, et al: Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. Am J Clin Pathol 115:814-822, 2001
86. Tanner M, Gancberg D, Di Leo A, et al: Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 157:1467-1472, 2000
87. Kumamoto H, Sasano H, Taniguchi T, et al: Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: Application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int 51:579-584, 2001
88. Veenstra DL, Higashi MK, Phillips KA: Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2:article 29, 2000
89. Bilous M, Dowsett M, Hanna W, et al: Current perspectives on HER2 testing: A review of national guidelines. Mod Pathol 16:173-182, 2003
90. Bast RC, Ravdin P, Hayes DF, et al: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society for Clinical Oncology. J Clin Oncol 19:1865-1878, 2001
91. Fitzgibbons PL, Page DL, Weaver D, et al: Prognostic factors in breast cancer: College of American Pathologists consensus statement 1999. Arch Path Lab Med 124:966-978, 2000